60,000 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Altium Capital Management LLC

Altium Capital Management LLC purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 60,000 shares of the company's stock, valued at approximately $2,624,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new stake in shares of Revolution Medicines during the 4th quarter valued at about $34,000. Sterling Capital Management LLC grew its holdings in Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares during the period. Farther Finance Advisors LLC increased its position in shares of Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after buying an additional 1,613 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock valued at $165,000 after buying an additional 3,178 shares in the last quarter. Finally, Avanza Fonder AB acquired a new stake in Revolution Medicines in the 4th quarter valued at $173,000. Hedge funds and other institutional investors own 94.34% of the company's stock.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. The trade was a 1.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Margaret A. Horn sold 3,058 shares of Revolution Medicines stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the sale, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This trade represents a 1.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,660 shares of company stock valued at $650,406. 8.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on RVMD shares. Needham & Company LLC reiterated a "buy" rating and issued a $59.00 target price on shares of Revolution Medicines in a research report on Tuesday, April 8th. Stifel Nicolaus cut their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. UBS Group raised their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright raised their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Finally, Wedbush reaffirmed an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $66.67.

Revolution Medicines Trading Down 0.5 %

RVMD traded down $0.20 during mid-day trading on Monday, hitting $36.56. 1,333,220 shares of the stock were exchanged, compared to its average volume of 1,423,960. The company has a market cap of $6.80 billion, a PE ratio of -10.18 and a beta of 1.37. The firm's fifty day moving average is $37.79 and its two-hundred day moving average is $44.39. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.